NCT03283462已完成不适用
A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Impact of a Daily Dose of AMAZ-02, a Food Derived Ingredient, for 4 Months on Skeletal Muscle Energetics and Function in Healthy Elderly
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Amazentis SA
- 入组人数
- 66
- 试验地点
- 1
- 主要终点
- Change in 6 minute walking distance (6MWD) at the end of study intervention compared to baseline
研究概览
简要总结
This is a randomized, double-blind, single-center, placebo-controlled Phase 2 trial enrolling 66 healthy elderly subjects (33 placebo and 33 AMAZ-02 administration) who are ≥65 and ≤ 90 years of age with evidence of low mitochondrial function. AMAZ-02 or placebo will be orally administered for 4 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 65 Years 至 90 Years（Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adults ≥65 and ≤90 years of age
- •Able to travel to and from the University of Washington and Fred Hutch Cancer Research Center (FHCRC)
- •Informed consent obtained
- •6 minute walk distance of <550 meters
- •ATP max < 1mM /sec (in the hand FDI muscle)
排除标准
- •Subjects who have significant disease(s) or condition(s) which, in the opinion of the investigator, may put the subject at risk because of their participation in the trial or may influence either the results of the trial or the subject's ability to participate in the trial
- •Hospitalization within 3 months for major atherosclerotic events (defined as combined incidence of myocardial infarction, urgent target-vessel revascularization, coronary bypass surgery and stroke) and for any hospitalization within 2 months.
- •Have any metal implants in the right limbs, including non-MRI compatible metal stents, titanium pins/markers, etc.
- •Have an implanted cardiac pacemaker or other implanted non-MRI compatible cardiac device
- •Chronic, uncontrolled hypertension as judged by the Investigator (i.e., Baseline SBP >150 mm Hg, DBP >90 mm Hg) or a SBP > 150 mm Hg or DBP > 95 mm Hg at the time of screening or baseline. If the initial BP reading is above these values, the reading may be repeated one time within 20 minutes of the initial reading.
- •Body mass index <18 or >32 kg/m2
- •Severe chronic kidney disease requiring treatment with hemodialysis or peritoneal dialysis.
- •Additional laboratory abnormalities determined as clinically significant by the Investigator.
- •Clinically significant abnormalities on physical examination (as judged by the Investigator)
- •Clinically significant and chronic uncontrolled renal, hepatic, pulmonary, endocrine, neurologic disorders, bone, or gastrointestinal system dysfunction
- •History of seizures or epilepsy
- •History of serious mental illness as judged by the Investigator
- •Oral temperature >37.5°C at the time of the physical
- •Suspicion, or recent history, of alcohol or substance abuse or tobacco use
- •Subjects who in the opinion of the Investigator have a clinically significant abnormal 12-lead ECG during the screening period. Presence of atrial fibrillation, varying degrees of AV block, existence of a left bundle branch block, or evidence of previous myocardial infarction.
- •Subjects who are either unwilling to agree to refrain from using or are found to be using supplementary antioxidant vitamins (e.g., Coenzyme Q10, resveratrol, L-carnitine) from 7 days prior to dosing and throughout the treatment period
- •Subjects who are either unwilling to agree to refrain from using or are found to be using the following dietary restrictions (pomegranate juice, walnuts, pecans, strawberry, raspberry blackberry) from 7 days prior to dosing and throughout the treatment period
- •Are currently enrolled in a clinical trial involving an investigational product or non-approved use of a drug or device or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
- •Have participated, within the last 30 days from a clinical trial involving an investigational product. If the previous investigational product has a long half life, 3 months or 5 half-lives (whichever is longer) should have passed
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebo (Dietary Supplement)
Mitopure
Active Comparator
干预措施: Mitopure (Dietary Supplement)
结局指标
主要结局
Change in 6 minute walking distance (6MWD) at the end of study intervention compared to baseline
时间窗: 4 months
Percent change from baseline in ATP max (maximal ATP synthesis rate) in hand skeletal muscle (via Magnetic Resonance Spectroscopy)
时间窗: 2, 4 months
次要结局
- Change in leg muscle strength (1-RM and 10-RM) at the end of study intervention compared to baseline(4 months)
- Change in muscle size (cross-sectional area of the muscles) at the end of study intervention compared to baseline(4 months)
- Percent change from baseline in contraction number during a hand muscle fatigue test(2, 4 months)
- Percent change from baseline in ATP max (maximum ATP synthesis rate) in leg skeletal muscle (via MRS)(4 months)
- Percent change from baseline in contraction number during a leg muscle fatigue test(4 months)
- Change in Short Physical Performance Battery (SPPB) scores at the end of study intervention compared to baseline(4 months)
- Change in exercise tolerance compared to baseline (via cycle ergometry)(4 months)
- Change in hand grip strength at the end of study intervention compared to baseline(4 months)
- Change from baseline in plasma lipid profile(4 months)
- Change in mitochondrial function on muscle biopsy samples at the end of study intervention compared to baseline (via respirometry)(4 months)
- Effect of AMAZ-02 on mitochondrial gene and protein expression in muscle tissue(4 months)
- Effect of AMAZ-02 on plasma acylcarnitines(4 months)
- Effect of AMAZ-02 on quality of life questionnaire (SF36)(4 months)
- Change from baseline in plasma for circulating biomarkers (myostatin, follistatin)(4 months)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Efficacy and Tolerance of Solriamfetol in Patients Affected with Idiopathic Hypersomnia.Idiopathic HypersomniaNCT06590662University Hospital, Montpellier60
已完成
2 期
A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy AdultsInfluenza ANCT02623322Genentech, Inc.124
终止
2 期
Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual ComponentsDyskinesiasParkinson DiseaseNCT04377945Bukwang Pharmaceutical41
已完成
2 期
Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast CancerBreast CancerNCT01186991Genentech, Inc.185
已完成
2 期
Safety and Efficacy of C21 in Subjects With COVID-19COVID-19NCT04452435Vicore Pharma AB206